No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
ABT Abbott Laboratories
- 100.070
- -4.610-4.40%
Close Jul 18 16:00 ET
- 100.550
- +0.480+0.48%
Post 19:59 ET
174.09BMarket Cap31.57P/E (TTM)
104.145High99.710Low13.08MVolume102.390Open104.680Pre Close1.32BTurnover0.76%Turnover Ratio30.70P/E (Static)1.74BShares120.39952wk High4.49P/B172.98BFloat Cap88.33252wk Low2.12Dividend TTM1.73BShs Float135.434Historical High2.12%Div YieldTTM4.24%Amplitude6.490Historical Low101.158Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Abbott Labs Lifts FY24 Outlook After 2Q Sales Rise
By Dean Seal Abbott Laboratories raised its full-year earnings guidance after reporting sales gains in the second quarter from its nutrition and medical devices segments. The Abbott Park, Ill.-based
Dow Plunges Over 500 Points Following Unexpected Surge In US Jobless Claims
The CNN Money Fear and Greed index showed a decline in the overall market sentiment, while the index moved to the "Neutral" zone on Thursday.U.S. stocks closed lower on Thursday, with the Dow Jones
TD Cowen Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $130
TD Cowen analyst Josh Jennings maintains $Abbott Laboratories(ABT.US)$ with a buy rating, and maintains the target price at $130.According to TipRanks data, the analyst has a success rate of 55.1%
Buy Rating Affirmed on Abbott Laboratories Amid Strong Q2 Results and Raised 2024 Guidance
Abbott CEO Warns of Health Crisis If Preterm Formula Pulled -- Market Talk
1504 ET - Abbott Laboratories has been hit with hundreds of lawsuits alleging its preterm infant formula and human milk fortifiers cause a life-threatening gastrointestinal disease affecting
Why Are Abbott Laboratories Shares Trading Lower?
Shares of Abbott Laboratories (NYSE:ABT) are trading lower on Thursday following the company's second-quarter 2024 financial results.What's Going On: Abbott reported second-quarter sales of $10.377
Comments
The earnings season is picking up speed, and this mid-July, we're about to get updates from some of the biggest names across various industries. Expect to hear from large banks, healthcare companies, airlines, and some of the tech and telecom giants that we all know.
The season started off last Friday with $JPMorgan(JPM.US$ , $Wells Fargo & Co(WFC.US$ , and $Wells Fargo & Co(WFC.US$ sharing their numbers. They all did bett...
The season started off last Friday with $JPMorgan(JPM.US$ , $Wells Fargo & Co(WFC.US$ , and $Wells Fargo & Co(WFC.US$ sharing their numbers. They all did bett...
+3
23
$Abbott Laboratories(ABT.US$
The stock has break below the support 101.56. Looks bearish. Next support is 100.64.
The stock has break below the support 101.56. Looks bearish. Next support is 100.64.
1
$Abbott Laboratories(ABT.US$
Bearish engulfing pattern appears in the chart. This stock has turned bearish. Next support is 101.56.
Bearish engulfing pattern appears in the chart. This stock has turned bearish. Next support is 101.56.
2
Morning Movers
Gapping up
$United Airlines(UAL.US$ stock rose 5.2% after the carrier forecast stronger-than-expected earnings in the current quarter and reported a narrower-than-expected loss in the first quarter, buoyed by robust demand for travel.
$Abbott Laboratories(ABT.US$ stock increased by 1.6% after the company surpassed quarterly profit expectations and raised the lower end of its earnings forecast, with strong dem...
Gapping up
$United Airlines(UAL.US$ stock rose 5.2% after the carrier forecast stronger-than-expected earnings in the current quarter and reported a narrower-than-expected loss in the first quarter, buoyed by robust demand for travel.
$Abbott Laboratories(ABT.US$ stock increased by 1.6% after the company surpassed quarterly profit expectations and raised the lower end of its earnings forecast, with strong dem...
31
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg